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doi:10.1016/j.ejvs.2009.02.022Abstract Objectives: To assess the predictive value of walking distance after an exercise test
on long-term outcome in patients with normal and impaired ankleebrachial index (ABI).
Design: A total of 2191 patients with known or suspected peripheral arterial disease (PAD), who
were referred for a single-stage treadmill exercise test to diagnose or evaluate their PAD, were
enrolled in an observational study between 1993 and 2006.
Materials and methods: They were divided into two groups: normal ABI (0.90) and impaired
ABI (<0.90). Walking distance was divided into quartiles (no (reference), mild, moderate or
severe impairment).
Results: In patients with normal ABI, severe walking distance was, after adjustment, associ-
ated with higher mortality risk (hazard ratio (HR): 2.60 (range: 1.16e5.78)).
In patients with impaired ABI, all walking distance impairment quartiles were associated
with higher mortality (mild HR: 1.26 (range: 0.95e1.67), moderate HR: 1.52 (range: 1.13e
2.05) and severe HR: 1.69 (range: 1.26e2.27)). Furthermore, comparable associations were
observed between all walking distance quartiles, cardiac death or major adverse cerebrovas-
cular and cardiac events.
Conclusions: Our study illustrated that walking impairment is a strong prognostic indicator of
long-term outcome in patients with impaired and normal ABI, which should be a warning sign to
physicians to monitor these patients carefully and to provide them optimal treatment.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.0 7040112/5956; fax: þ31 10 4633639.
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Association Between Walking Impairment and Outcome 483Peripheral arterial disease (PAD) is associated with an
increased risk of cardiovascular morbidity and mortality.1,2
To diagnose or to evaluate PAD, the ankleebrachial index
(ABI; the ratio between the ankle and brachial systolic
blood pressure) is used.2,3 Several studies have shown that
ABI is an independent risk factor for cardiovascular diseases
and mortality.1,2,4e7 Patients with PAD experience signifi-
cant limitation in their physical functioning, and walking in
particular.8e13 However, in contrast to the clinical value of
the ABI, the clinical value of this walking disability is still
unclear. It has been shown previously that in patients with
impaired left ventricular function or congestive heart
failure, the distance during a 6-min walk test was a strong
and independent predictor of morbidity and mortality.14 In
addition, a large cohort study in well-functioning commu-
nity-based older adults observed that the inability to
complete a 400-m walking test and a decrease in perfor-
mance time resulted in higher mortality, cardiovascular
events and mobility limitations.15 Nevertheless, only very
few studies investigated the effects of physical activity on
long-term outcome and mostly in patients with impaired
ABI.16e19 Therefore, we performed a large observational
study to assess the predictive value of the walking distance
after a single-stage exercise test on long-term all-cause
mortality, cardiac death and major adverse cerebrovas-




Our study population consisted of 2191 patients, who were
referred by general practitioners or physicians to the
vascular laboratory of the Erasmus Medical Centre, Rot-
terdam, the Netherlands, for a single-stage treadmill
exercise test, between 1993 and 2006. Our population
represents a mixture of daily clinical practice of our
vascular laboratory. Patients were referred by physicians to
diagnose PAD based on their presenting symptoms, or those
who already had a history of intermittent claudication or
other symptoms of arterial insufficiency were sent to
evaluate their PAD. Excluded were those patients who were
unable to perform the treadmill exercise test. The hospital
medical ethics committee approved the study and the
patients gave permission to use their data.
Single-stage exercise test
Specialised trained personnel supervised the exercise tests
using a prescribed protocol. The systolic blood pressure was
measuredwith a blood pressure device (Maxi stable 3, presso
stabl; Welch Allyn Inc, Skaneateles Falls, New York, USA) at
both left and right arms in supineposition after 15min rest. In
addition, the blood pressure at the dorsalis pedis and pos-
terial tibial arteries were measured at both sides using
a Doppler ultrasonic instrument with an 8-MHZ vascular
probe (Imexdop CT þ vascular Doppler; Miami Medical, Gle-
nAllen, VA,USA). Following thesemeasurements, all patients
were asked towalk on a treadmill with a speed of 4 kmh1 for
a maximum of 5 min. No inclining plane or graded inclineswere used. During the walking test, patients were asked to
inform the personnel themoment they felt pain in their legs.
Patients were encouraged to finish the whole test, but the
test was stopped when the patient was unable to walk
further. Time and walking distance till the occurrence of leg
pain and the total walking time and distance were recorded.
Immediately after the exercise, the systolic blood pressure
at the arm, as well as at the dorsalis pedis or posterial tibial
artery, depending which one was highest at rest, was
measured in supine position. ABI at rest and after the exer-
cise test was calculated by dividing the highest systolic blood
pressure at the arm by the systolic blood pressure at the
dorsalis pedis and posterial tibial arteries, based on which
one was the highest. As described previously, the inter-
observer and intra-observer agreement for the resting ABI
was 97% and 98%, and for the exercise ABI, 96% and 97%.4 All
variables were incorporated in a computerised hospital
database. Patients were defined as having an impaired ABI,
when the lowest resting or exercise ABI was<0.90. Following
these criteria, 1624 patients (74%) were considered as having
an impaired ABI.
Covariate assessment
From the medical records, the following baseline charac-
teristics were noted: age, gender, current smoking status,
diabetes mellitus, hypercholesterolaemia, hypertension,
chronic obstructive pulmonary disease, baseline medication
use (statin, beta-blockers, ace-inhibitors and aspirin), renal
dysfunction, history of congestive heart failure, history of
cardiac disease consisted of angina pectoris, myocardial
infarction or coronary artery re-vascularisation. The
following definitions were used for the different covariates.
Diabetes mellitus was documented when patients presented
with the diagnosis, made by the referred physician, required
anti-diabetic medication, having a fasting glucose level
126 mg dl1, a glucose level of 200 mg dl1 after an oral
glucose tolerance test or plasmanon-fasting glucose levels of
200 mg dl1.20,21 Hypertension was recorded if a patient
had a blood pressure higher >140/90 mmHg or treated with
anti-hypertensive medication. Chronic obstructive pulmo-
nary disease was classified as a history of chronic obstructive
pulmonary disease or pulmonary medication use. Hyper-
cholesterolaemia was noted when patients presented with
thediagnosis,madeby the referredphysician, received lipid-
lowering medication or a plasma cholesterol level of
212 mg dl or more. Renal dysfunction was defined as having
a serum creatinine level of 2.0 mg dl1 or receiving
dialyses.Follow-up
The follow-up vital status, which was obtained by reviewing
the civil registries, was completed for 99.4%. The survival
status of six patients who had moved abroad could not be
retrieved, and the last available follow-up data were used.
The cause of death was obtained from the Central Bureau
of Statistics or from medical records. Of 62 patients (10%),
no course of death could be traced. In addition, self-
reporting questionnaires about cardiac events were sent to
all survivors, of whom 73% returned the questionnaire.
Table 1 Baseline characteristics in patients with normal










(n Z 1624; 74%)
Age (years) 59  14 64  11
Body mass
index (kg/m2)
26  5 26  7
Male (%) 338 (60) 1131 (70)
Chronic obstructive
pulmonary disease (%)
62 (11) 220 (14)
Hypertension (%) 161 (29) 639 (40)
Diabetes mellitus (%) 91 (16) 322 (20)
Smoking (%) 147 (26) 555 (35)
Hypercholesterolaemia (%) 121 (22) 435 (27)
Renal failure (%) 37 (7) 103 (6)
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The exercise total walking distance were categorised into
quartiles (no (reference), mild, moderate, severe walking
impairment) for each group. Cox proportional hazard ratios
with 95% confidence interval (95% CI) were calculated to
define the relationship between the exercise total walking
distance and long-term all-cause mortality, cardiac death
and MACCE. MACCE consisted of cardiac or cerebrovascular
death or major adverse cardiac events such as angina
pectoris, non-fatal myocardial infarction, coronary artery
bypass grafting or percutaneous coronary angioplasty.
Adjustments were made for potential clinical risk factors
and exercise ABI. All analyses were repeated after
excluding patients with diabetes mellitus. The Kaplane
Meier method with log-rank tests was used to compare
survival of the four quartiles of the total walking distance.
For all tests, significance was defined as a p-value of 0.05.
Analyses were performed in SPSS 14 for Windows.History of cardiac
disease (%)
160 (29) 567 (35)
History of heart
failure (%)




140  24 155  26
Resting ankle
brachial index
1.06  9 0.67  20
Total exercise
walking distance (m)
253  95 218  98
Exercise systolic
blood pressure (mmHg)
156  30 182  34
Exercised ankle
brachial index
1.02  9 0.44  24
Values are means with standard deviations or numbers with
percentages.Results
The mean age of the total population was 62 years and 67%
were men. Table 1 shows baseline characteristics of
patients with impaired and normal ABI. Patients with
impaired resting ABI were older, included more number of
males, had more prevalent hypertension and were more
often current smokers. As expected, the total walking
distance was less in patients with impaired ABI compared to
patients with normal resting ABI. In patients with normal
ABI, the total walking distance for the four quartiles were:
321 m or more in the no-impairment (reference) group,
between 312 and 321 m in mild impairment group, between
174 and 312 m in moderate impairment group and 174 m or
less in the severe impairment group. In the patients with
impaired ABI, the total walking distance in the patients
with no impairment (reference) was 318 m or more, mild
impairment was between 233 and 318 m, moderate
impairment between 126 and 233 m and patients with
a severe impairment had a walking distance of 126 m or
less.
The mean follow-up period was 5 years, ranging from 1
month to 14 years. During the follow-up period, 13%
patients with normal ABI and 34% in the impaired ABI group
died. Cardiac death and MACCE occurred in 5% and 12% in
patients with normal ABI and 19% and 36% in the impaired
ABI group.
In patients with normal ABI, a severe impairment in
exercise total walking distance was, after adjustments of
clinical risk factors and exercise ABI, independently asso-
ciated with an increased risk of all-cause mortality (Table 2a).
The cumulative mortality and cardiac death survival curves
of both moderate and severe impairment walking
distances, shown in Fig. 1, were significantly worse
compared to the no-impairment quartile group.
In patients with impaired ABI, all impairment total
walking distance quartiles were associated with an
increased risk of all-cause mortality, cardiac death and
MACCE, independent of clinical risk factors or exercise ABI
(Table 2b). The risk of all-cause mortality, cardiac death
and MACCE increased proportionally when the exercisetotal walking distance became worse (Table 2b). The log-
rank tests of the cumulative survival of all three impair-
ment walking distance quartiles in the patients with an
impaired ABI were significantly worse compared to no-
impairment total walking distance (Fig. 2).
Comparable results were seen for all analyses when
repeated at 5 years’ follow-up. Results did not substantially
differ when all analyses were repeated with additional
adjustments for date of enrolment, baseline medication
use (statins, beta-blockers, ace-inhibitors, aspirin) or after
excluding patients with baseline diabetes mellitus or with
severe ABI impairment (ABI < 0.50).
Discussion
Our study showed that in patients with a normal resting ABI,
a severe impairment in single-stage treadmill exercise total
walking distance was associated with a higher mortality
rate, independent of other cardiovascular risk factors. In
patients with an impaired resting ABI as well, impairment in
total walking distance was highly associated with an
increased risk of long-term outcome, again independent of
other cardiovascular risk factors or ABI.
Table 2 Hazard ratios (HRs) with 95% confidence interval (CI) of total walking distance with long-term all-cause mortality,
cardiac death and major adverse cerebrovascular and cardiac events (MACCE).
Model I (HR, 95% CI) Model II (HR, 95% CI) Model III (HR, 95% CI)
(a) Patients with normal ankle brachial index
Total walking distance
All-cause mortality
I no impairment Ref Ref Ref
II mild impairment 1.70 (0.74, 3.89) 1.69 (0.73, 3.94) 1.70 (0.73, 3.98)
III moderate impairment 1.52 (0.69, 3.39) 1.57 (0.70, 3.53) 1.57 (0.70, 3.54)
IV severe impairment 2.72(1.24, 5.98) 2.60(1.17, 5.80) 2.60 (1.16, 5.78)
Cardiac death
I no impairment Ref Ref Ref
II mild impairment 0.82 (0.18, 3.67) 1.05 (0.22, 5.00) 1.02 (0.21, 4.82)
III moderate impairment 1.29 (0.37, 4.54) 1.44 (0.39, 5.28) 1.39 (0.38, 5.09)
IV severe impairment 3.00 (0.90, 9.89) 2.74 (0.81, 9.32) 2.76 (0.82, 9.34)
MACCE
I no impairment Ref Ref Ref
II mild impairment 0.61 (0.24, 1.57) 0.75 (0.26, 2.02) 0.73 (0.27, 2.00)
III moderate impairment 0.96 (0.41, 2.27) 0.88 (0.37, 2.07) 0.86 (0.36, 2.04)
IV severe impairment 1.96 (0.87, 4.41) 1.63 (0.72, 3.73) 1.50 (0.65, 3.47)
(b) Patients with impaired ankle brachial index
Total walking distance
All-cause mortality
I no impairment Ref Ref Ref
II mild impairment 133 (1.00,1.76) 1.27 (0.96,1.69) 1.26 (0.95,1.67)
III moderate impairment 1.62 (1.21,2.16) 1.56 (1.16,2.10) 1.52 (1.13,2.05)
IV severe impairment 1.83 (1.38,2.44) 1.73 (1.29,2.32) 1.69 (1.21,2.27)
Cardiac death
I no impairment Ref Ref Ref
II mild impairment 1.29 (0.85,1.97) 1.18 (0.77,1.80) 1.16 (0.76,1.77)
III moderate impairment 1.66 (1.09,2.54) 1.62 (1.06,2.48) 1.55 (1.01,2.38)
IV severe impairment 1.91 (1.28,2.98) 1.73 (1.13,2.66) 1.67 (1.08,2.57)
MACCE
I no impairment Ref Ref Ref
II mild impairment 1.62 (1.62,2.25) 1.46 (1.05,2.03) 1.44 (1.03,2.00)
III moderate impairment 1.87 (1.87,2.60) 1.75 (1.25,2.45) 1.69 (1.20,2.37)
IV severe impairment 2.47 (1.77,3.44) 2.05 (1.46,2.88) 2.00 (1.41,2.80)
Model I Z age and gender.
Model II Z Model I þ current smoking at baseline, hypertension, chronic obstructive pulmonary disease, hypercholesterolaemia, dia-
betes mellitus, history of congestive heart failure, previous cardiovascular diseases, renal failure and resting systolic blood pressure.
Model III Z Model II þ exercise ankle brachial index.
Bold characters are significant values with p-value 0.05.
HR Z hazard ratio; CI Z confidence interval.
Association Between Walking Impairment and Outcome 485The ABI is used to assess peripheral arterial stenosis.3
Values less than 0.90 are associated with vessel stenosis of
more than 50%.2 Currently, the ABI is commonly used to
diagnose or evaluate PAD.2,3 Several studies have found
that ABI < 0.90 is associated with an increased risk of
cardiovascular diseases and mortality.4e6 Furthermore,
PAD and low ABI have been associated with a lower level of
exercise and physical activity, worse lower-extremity
functioning, shorter walking distance on the 6-min walking
test, slower walking velocity and poorer standing balan-
ce.8e13 However, in contrast to the clinical value of the
ABI, the clinical value of the walking disability on long-
term outcome is unclear, especially in patients with
a normal ABI.In contrast to the results obtained by McDermott et al.,
we observed that, in 849 patients with a normal resting ABI,
a severe impairment in total walking distance was associ-
ated with a higher long-term mortality.18 This difference
could be due, as they noted themselves, to their small
sample size and short follow-up time (3e5 years).18 Our
results could not be compared with other studies because,
to the best of our knowledge, no other researches have yet
investigated the effects of walking distance in patients with
an ABI  0.90 on mortality risks.
There are a few possible explanations for this increased
risk of long-term mortality in patients with a normal resting
ABI. First, it can be hypothesised that these results could be
due to the diabetic patients in this study group. Patient
Figure 1 Survival curves of the four total walking distance
quartiles in patients with normal ankle brachial index for long-
term all-cause mortality (a) and cardiac death (b).
Figure 2 Survival curves of the four total walking distance
quartiles in patients with impaired ankle brachial index for
long-term all-cause mortality (a) and cardiac death (b).
486 I.I. de Liefde et al.with diabetes mellitus, although having an increased risk of
cardiovascular morbidity and mortality, are known to have
higher ABI.2,22,23 This is thought to be because of serious
calcification of vessels. This results in high vessel-wall
rigidity and therefore abnormal highly measured systolic
blood pressures in the legs, resulting in a high ABI.2,22,23
However, we adjusted for baseline diabetes mellitus in the
analyses. In addition, we made additional analyses by
excluding patients with baseline diabetes mellitus, which
did not substantially change our results. Other confounders
such as chronic obstructive pulmonary disease and chronic
heart failure could have influenced the results as well.
However, we adjusted our analyses for these and other
potential risk factors. Second, there is a possibility that
patients in the normal resting ABI group had PAD, but that it
was not reflected by the ABI.24 It is possible that the cut-off
value of 0.90 is not appropriate. Diehm et al. showed that
patients with an ABI value between 0.90 and 1.10 had an
increased risk of death or major vascular events compared
with patients with an ABI of 1.10.7 They state that these
patients should be considered as borderline PAD patientsand must be followed up closely. The same could be true
for our patients; although not reflected by the ABI, these
patients have a higher long-term mortality risk.
In patients with an impaired ABI, we observed that
exercise walking distance was associated with an adverse
long-term outcome, independent of other cardiovascular
risk factors or ABI. Only a few studies investigated the
effects of these impaired physical functioning on long-term
outcome in patients with PAD.16e19 Gardner et al. found
that patients with PAD, who performed 1 h physical activity
each week, had a lower mortality risk compared to PAD
patients who did not perform physical activity at all or less
than recommended.16 Their results were comparable with
Schiano et al. who observed that self-reported walking
speed and walking distance from the Walking Impairment
Questionnaire in PAD patients was associated with a higher
risk of developing cardiovascular events.19 However, they
did not measure the physical activity objectively, as we did.
In addition, both researches had a relatively small sample
size (434 and 227 patients, respectively) compared to ours
(2191 patients). A third small study in 460 PAD patients
found that lower physical activity during daily life,
Association Between Walking Impairment and Outcome 487objectively measured by a vertical accelerometer, was
associated with higher mortality, cardiovascular events and
cardiovascular death rates.17 McDermott et al. showed
that, comparable to our results, the walking distance in
patients with PAD was significantly associated with all-
cause mortality and cardiovascular death.18
In conclusion, our study illustrated that walking impair-
ment is a strong independent prognostic indicator of long-
term outcome in patients with impaired ABI and in patients
with a normal ABI, which should be a warning sign to
physicians to monitor these patients carefully and to
provide them optimal treatment.
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